India's pharmaceutical business continues to expand rapidly, with the sector playing an increasingly important role in defining global healthcare. The Indian pharma industry is a mix of established market giants and creative young stars. The top 20 Indian pharmaceutical Companies in India are influencing international healthcare trends, supporting innovation, and enhancing India's status as a key center for generic and specialty medications.
Major businesses like as Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, and Lupin have cemented India's position in the global pharmaceutical sector. At the same time, rising firms like Steris Healthcare Pvt Ltd are making significant advances in price, quality, and expansion, providing fresh energy and direction to the market.
The Top 20 Pharmaceutical Companies in India for FY2025 are listed in detail below, sorted by market capitalization, innovation, and operational scale:
1. Sun Pharmaceutical Industries Limited.
FY25 revenue: ₹52,041 crore (9% YoY increase).
Highlight: India's largest pharmaceutical corporation, with an 8% market share and sales of $1.92 billion in the United States.
Overview: Sun Pharma is the world's fourth biggest specialized generic pharmaceutical firm. The firm has a varied portfolio that includes carbamazepine, etodolac, clorazepate, anti-cancer medications, steroids, and others. It operates in 150 countries and has companies such as Ranbaxy Laboratories and Sun Ophthalmic Inc.
2. The Laboratory of Dr. Reddy, Ltd.
Revenue for FY25: ₹31,229 crore
Highlights: extensive product pipeline; 47% of sales comes from the United States.
Summary: Dr. Reddy's is a worldwide pharmaceutical firm that was founded in 1984 and offers more than 190 medications and 60 APIs. Among the main products are drugs such as atorvastatin, ramipril, and canagliflozin.
3. Aurobindo Pharma
Revenue for FY25: ₹30,922 crore
Highlight: Top exporter of APIs and generics, with operations in more than 150 nations.
Summary: The firm was founded in 1986 and now offers more than 300 goods worldwide. It is particularly effective in antiviral, cardiovascular, and neurological treatments.
4. Steris Healthcare Pvt. Ltd.
FY25 Income: more than ₹110.68 crore
Head Office: Navi Mumbai
Highlight: Specialty product lines from a rapidly expanding pharmaceutical firm. Revenue just surpassed ₹100 crore, and 800+ new positions and an impending IPO were announced.
Overview: Established in May 2018 by seasoned pharmaceutical professionals, Steris Healthcare offers a wide range of affordable specialty medicines. The company is gaining recognition for its quality, WHO-GMP-certified formulations across therapeutic areas like cardiology, diabetology, gastroenterology, orthopedics, neurology, gynecology, pediatrics, dermatology, and oncology.
5. Cipla Ltd.
Revenue for FY25: ₹26,982 crore
Highlight: Exports account for over half of income; the company is a pioneer in HIV and respiratory therapies.
Overview: Cipla is a biotech and pharmaceutical behemoth that was founded in 1935 and specializes in CNS, diabetes, arthritis, and cardiovascular diseases.
6. Zydus Lifesciences
- Revenue for Zydus Lifesciences in FY25: ₹22,247 crore
Highlight: excellent in managing chronic diseases; receives 45% of revenue from the United States.
Summary: Zydus was established in 1952 and is well-known for its voluntary approved hepatitis C generics, cosmetics, herbal items, and diagnostics. Its production facilities are located in Ankleshwar, Patalganga, and Vadodara.
7. Lupin Ltd.
Revenue for FY25: ₹22,002 crore
The respiratory and metabolic divisions are robust, accounting for 37% of U.S. sales.
Overview: Founded in 1968, Lupin produces medications for diabetes, cardiovascular disease, TB, asthma, and pediatrics. In India, its market worth places it in 12th place.
8. Biocon Ltd.
Revenue for FY25: ₹14,762 crore
Highlight: 44% of sales comes from the United States; leading biosimilars player.
Overview: Bengaluru-based Biocon was established in 1978 and specializes in biosimilars and generic APIs. It has more than 9,000 professional employees and is well-known across the world for its innovation and research.
9. Glenmark Pharmaceuticals
FY25 revenue: ₹13,128 crore.
Highlight: Active in over 80 countries; pioneer in dermatology, respiratory, and cancer.
Glenmark, founded in 1977, focuses on biosimilars and new medicines, aided by partnerships with multinational pharmaceutical companies.
10. Alkem Laboratories
FY25 revenue: ₹12,757 crore.
Highlight: Strong domestic market presence; OTC and prescription product offerings.
Established in Mumbai, Alkem has 21 production units (19 in India, 2 in the US) and is recognized for pharmaceuticals like Taxim, which was the first Indian anti-infective drug to achieve ₹1,000 million in sales.
11. Torrent Pharmaceuticals
FY25 revenue: ₹11,302 crore.
Highlight: Expertise in cardiovascular and CNS medications.
Overview: Torrent, headquartered in Ahmedabad, manufactures medications for the central nervous system, the gastrointestinal tract, diabetes, and pain treatment. Its manufacturing facilities are located in Dahej and Pithampur.
12. Mankind Pharma
FY25 Revenue: ₹9,326 crore
Highlight: Dominant in OTC and gynecology; rapidly expanding prescription business.
Overview: Headquartered in New Delhi and founded in 1995, Mankind offers a vast portfolio including antibiotics, NSAIDs, dermal, ED medications, and more.
13. Divi's Laboratories
FY25 Revenue: ₹9,078 crore
Highlight: Among top API exporters worldwide; Q4 profit ₹667 crore.
Overview: Founded in 1990, Divi's is a leader in APIs and intermediates, exporting to 95+ countries. It offers nutraceuticals and custom synthesis services.
14. Piramal Enterprises
FY25 revenue: ₹8,949 crore.
Highlight: A diverse business in diagnostics, manufacturing, and life sciences.
Overview: Ajay Piramal acquired the company, which works in medicines, critical care, and consumer products with a strong R&D base.
15. IPCA Laboratories
FY25 revenue: ₹8,726 crore.
Highlight: A major participant in API exports and the anti-inflammatory and anti-malarial markets.
Overview: Known for its steady export performance and extensive API portfolio.
16. Abbott India
Highlight: A multinational subsidiary with significant skills in pharmaceuticals, diagnostics, and nutrition.
Overview: As part of the Abbott group headquartered in the United States, it provides high-quality medications and nutritional goods in India.
17. Alembic Pharmaceuticals
Highlight: Specialized in anti-retroviral and oncology drugs.
Overview: Based in Gujarat, Alembic boasts modern manufacturing facilities and a growing portfolio of niche therapeutic products.
18. Emcure Pharmaceuticals
Highlight: Expanding in India, Europe, and the U.S. with generics and biosimilars.
Overview: Recognized for innovation and speed to market in specialty and biosimilar segments.
19. Natco Pharma
Highlight: Trusted for cancer treatment affordability and complex generics.
Overview: Focuses heavily on oncology, with a reputation for producing high-quality, low-cost cancer medications.
20. Laurus Labs
Highlight: Global leader in APIs; expanding into biotech, CDMO, and nutraceuticals.
Overview: Known for vertical integration, Laurus Labs is carving a niche in contract development and manufacturing.
Why Steris Healthcare Pvt Ltd Stands Out in India's Pharma Industry
In a highly competitive landscape, Steris Healthcare Pvt Ltd is emerging as a brand to watch. Founded in 2018, Steris has built a strong reputation for manufacturing WHO-GMP-certified, affordable, and effective medications that serve a wide spectrum of therapeutic needs. The company's fast growth is attributed to its unwavering focus on quality, patient safety, and innovation.
One of the primary reasons behind Steris Healthcare's success is its unwavering commitment to quality. The company holds various prestigious certifications, including:
WHO (World Health Organization) Certification: This ensures that Sterispharma's manufacturing processes meet international health and safety guidelines.
GMP (Good Manufacturing Practice) Certification: This guarantees that the company follows stringent production practices, ensuring high-quality and safe medicines.
ISO (International Organization for Standardization) Certification: This accreditation reflects Steris Healthcare's commitment to maintaining global standards in pharmaceutical production and quality control.
These certifications validate the company's promise of delivering safe and effective medications to the Indian market while complying with international pharmaceutical regulations.
Steris Healthcare Pvt Ltd operates a PCD Pharma Franchise business model, allowing entrepreneurs and businesses to partner with them in distributing pharmaceutical products. The franchise model provides excellent opportunities for individuals looking to enter the pharmaceutical business with the backing of a well-established brand.
The company also operates a PCD Pharma Franchise model, allowing business partners to collaborate and expand its distribution network across India.
Best PCD pharma franchise company to handle many clients, we offer a wide range of pharmaceutical products, including cardiology, respiratory, gastro, and chronic disease medications. Now, you can conveniently buy medicine online from Steris and get safe, effective treatments delivered to your doorstep. Choose Steris Healthcare for premium healthcare solutions.
